Eloxatin 5mg/ml, Concentrate for Solution for infusion

Manufacturer
Sanofi-Aventis Deutschland GmbH
 
Contents
Oxaliplatin
 
Indication
In combination w/ 5-fluorouracil & folinic acid, adjuvant treatment of stage III (Dukes' C) colon cancer after complete resection of the primary tumor & for treatment of metastatic colorectal cancer.
 
Instruction
Administer via IV Infusion.
 
Drug interaction
In vitro, no significant displacement of oxaliplatin binding to plasma proteins has been observed with the following agents: Erythromycin, salicylates, granisetron, paclitaxel and sodium valproate.
No clinical drug interaction studies between oxaliplatin and 5-fluorouracil have been conducted.
Incompatibilities: Do not use in association with alkaline drugs or solutions (in particular 5-fluorouracil basic solution, trometamol) or chlorides including sodium chloride, at all concentrations.
Do not mix with other drugs. Oxaliplatin may be degraded on contact with aluminum. Equipment containing aluminum should not be used for the administration of oxaliplatin.
 


 Inquiry - Eloxatin 5mg/ml, Concentrate for Solution for infusion